Table 1 Baseline characteristics of the present study population (162 women with ovarian, tubal, and peritoneal cancer).

Age at diagnosis, years

52 (47–61)

52 (47–61)

52.5 (47–60)

BMI, kg/m²

22.8 (21–24.8)

22.7 (20.9–24.7)

22.8 (21.2–25)

FIGO stage

  I

13 (8.0%)

12 (15.8%)

1 (1.2%)

  II

45 (27.8%)

25 (32.9%)

20 (23.3%)

  III

67 (41.4%)

28 (36.8%)

39 (45.3%)

  IV

37 (22.8%)

11 (14.5%)

26 (30.2%)

Tumor origin

  Ovary

143 (88.3%)

67 (88.2%)

76 (88.4%)

  Fallopian tube

12 (7.4%)

7 (9.2%)

5 (5.8%)

  Peritoneum

7 (4.3%)

2 (2.6%)

5 (5.8%)

CA125 at diagnosis, U/mL

   ≤ 500

54 (33.3%)

32 (42.1%)

22 (25.6%)

   ≤ 1000

45 (27.8%)

20 (26.3%)

25 (29.1%)

   ≤ 2000

23 (14.2%)

9 (11.8%)

14 (16.3%)

   > 2000

40 (24.7%)

15 (19.7%)

25 (29.1%)

Primary treatment

  NACT + IDS

72 (44.4%)

27 (35.5%)

45 (52.3%)

  PDS + ACT

90 (55.6%)

49 (64.5%)

41 (47.7%)

  Median number of chemotherapy cycles

7

7.5

7

Surgical procedures

  Pelvic lymphadenectomy

65 (40.1%)

32 (42.1%)

33 (38.4%)

  Para-aortic lymphadenectomy

26 (16.0%)

12 (15.8%)

14 (16.3%)

  Abdominal organ resection

13 (8.0%)

8 (10.5%)

5 (5.8%)

  Distant metastases resection

15 (9.3%)

2 (2.6%)

13 (15.1%)

Operation time, min

188 (150–236)

188.5 (150–227.5)

188 (150–238.5)

Blood loss, mL

200 (100–400)

200 (100–400)

200 (100–410)

Surgical outcome

  RT = 0

100 (61.7%)

54 (71.1%)

46 (53.5%)

  RT < 1 cm

35 (21.6%)

16 (21.1%)

19 (22.1%)

  RT ≥ 1 cm

27 (16.7%)

6 (7.9%)

21 (24.4%)

Histologic grade

  High-grade serous

127 (78.4%)

52 (68.4%)

75 (87.2%)

  Low-grade serous

15 (9.3%)

12 (15.8%)

3 (3.5%)

  Serous not specified

20 (12.3%)

12 (15.8%)

8 (9.3%)